Premium
Serum level of circulating syndecan‐1: A possible association with proliferative vasculopathy in systemic sclerosis
Author(s) -
Wu ChingYing,
Asano Yoshihide,
Taniguchi Takashi,
Sato Shinichi,
Yu HsinSu
Publication year - 2016
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.12986
Subject(s) - pathogenesis , syndecan 1 , telangiectasia , medicine , inflammation , gastroenterology , disease , systemic scleroderma , immunology , pathology , endocrinology , biology , cell , genetics
Syndecan‐1 is a member of the transmembrane heparan sulfate proteoglycan family, whose membrane‐bound and soluble forms are involved in wound healing, inflammation and vascular biology. Because these physiological events are implicated in the pathogenesis of systemic sclerosis ( SS c), we investigated the clinical association of serum syndecan‐1 levels in this disease. Serum syndecan‐1 levels were significantly higher in SS c patients, both in diffuse cutaneous SS c (dc SS c) and limited cutaneous SS c (lc SS c), than in healthy individuals, while comparable between dc SS c and lc SS c groups. In late stage dc SS c patients (disease duration of >6 years), but not non‐late stage dc SS c patients (≤6 years), serum syndecan‐1 levels were significantly higher than in normal controls. More importantly, SS c patients with elevated serum syndecan‐1 levels had higher prevalence of telangiectasia, elevated right ventricular systolic pressure and decreased diffuse capacity of the lung for carbon monoxide than those with normal levels. Therefore, soluble syndecan‐1 may be related to the development of proliferative vasculopathy in SS c patients.